PortalPublikationenShould patients with high-risk or transformed myelodysplasti...

Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?

Standard

Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy? / de Witte, Theo M; Bowen, David; Robin, Marie; Malcovati, Luca; Mufti, Ghulam; Niederwieser, Dietger; Yakoubagha, Ibrahim; Kröger, Nicolaus; Myelodysplastic Syndrome Stem Cell Transplant Guidelines Preparation Group from the Chronic Malignancies Working Party, European Group for Blood and Marrow Transplantation and European LeukemiaNet.

in: CL LYMPH MYELOM LEUK, Jahrgang 14 Suppl, 01.09.2014, S. S42-5.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

de Witte, TM, Bowen, D, Robin, M, Malcovati, L, Mufti, G, Niederwieser, D, Yakoubagha, I, Kröger, N & Myelodysplastic Syndrome Stem Cell Transplant Guidelines Preparation Group from the Chronic Malignancies Working Party, European Group for Blood and Marrow Transplantation and European LeukemiaNet 2014, 'Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?', CL LYMPH MYELOM LEUK, Jg. 14 Suppl, S. S42-5. https://doi.org/10.1016/j.clml.2014.06.015

APA

de Witte, T. M., Bowen, D., Robin, M., Malcovati, L., Mufti, G., Niederwieser, D., Yakoubagha, I., Kröger, N., & Myelodysplastic Syndrome Stem Cell Transplant Guidelines Preparation Group from the Chronic Malignancies Working Party, European Group for Blood and Marrow Transplantation and European LeukemiaNet (2014). Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy? CL LYMPH MYELOM LEUK, 14 Suppl, S42-5. https://doi.org/10.1016/j.clml.2014.06.015

Vancouver

de Witte TM, Bowen D, Robin M, Malcovati L, Mufti G, Niederwieser D et al. Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy? CL LYMPH MYELOM LEUK. 2014 Sep 1;14 Suppl:S42-5. https://doi.org/10.1016/j.clml.2014.06.015

Bibtex

@article{77da7fb5e8374aa2ab055e12a8084f8b,
title = "Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?",
abstract = "The selection of a treatment strategy before allogeneic hematopoietic stem cell transplant (HSCT) for myelodysplastic syndrome is a delicate process. The expected relapse risk and nonrelapse mortality after HSCT and the response rates to the pretransplant strategies all play a role in this process. Fit patients younger than 60 to 65 years with > 10% marrow blasts and without high-risk cytogenetic abnormalities should be seriously considered for intensive chemotherapy (ICT) to reduce tumor load before HSCT. Other patients up to the age of 75 years may be considered for hypomethylating agent therapy before transplant. Patients with high-risk cytogenetic abnormalities should be treated in investigational protocols if they are not candidates for ICT.",
author = "{de Witte}, {Theo M} and David Bowen and Marie Robin and Luca Malcovati and Ghulam Mufti and Dietger Niederwieser and Ibrahim Yakoubagha and Nicolaus Kr{\"o}ger and {Myelodysplastic Syndrome Stem Cell Transplant Guidelines Preparation Group from the Chronic Malignancies Working Party, European Group for Blood and Marrow Transplantation and European LeukemiaNet}",
note = "Copyright {\textcopyright} 2014 Elsevier Inc. All rights reserved.",
year = "2014",
month = sep,
day = "1",
doi = "10.1016/j.clml.2014.06.015",
language = "English",
volume = "14 Suppl",
pages = "S42--5",
journal = "CL LYMPH MYELOM LEUK",
issn = "2152-2650",
publisher = "Cancer Media Group",

}

RIS

TY - JOUR

T1 - Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?

AU - de Witte, Theo M

AU - Bowen, David

AU - Robin, Marie

AU - Malcovati, Luca

AU - Mufti, Ghulam

AU - Niederwieser, Dietger

AU - Yakoubagha, Ibrahim

AU - Kröger, Nicolaus

AU - Myelodysplastic Syndrome Stem Cell Transplant Guidelines Preparation Group from the Chronic Malignancies Working Party, European Group for Blood and Marrow Transplantation and European LeukemiaNet

N1 - Copyright © 2014 Elsevier Inc. All rights reserved.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - The selection of a treatment strategy before allogeneic hematopoietic stem cell transplant (HSCT) for myelodysplastic syndrome is a delicate process. The expected relapse risk and nonrelapse mortality after HSCT and the response rates to the pretransplant strategies all play a role in this process. Fit patients younger than 60 to 65 years with > 10% marrow blasts and without high-risk cytogenetic abnormalities should be seriously considered for intensive chemotherapy (ICT) to reduce tumor load before HSCT. Other patients up to the age of 75 years may be considered for hypomethylating agent therapy before transplant. Patients with high-risk cytogenetic abnormalities should be treated in investigational protocols if they are not candidates for ICT.

AB - The selection of a treatment strategy before allogeneic hematopoietic stem cell transplant (HSCT) for myelodysplastic syndrome is a delicate process. The expected relapse risk and nonrelapse mortality after HSCT and the response rates to the pretransplant strategies all play a role in this process. Fit patients younger than 60 to 65 years with > 10% marrow blasts and without high-risk cytogenetic abnormalities should be seriously considered for intensive chemotherapy (ICT) to reduce tumor load before HSCT. Other patients up to the age of 75 years may be considered for hypomethylating agent therapy before transplant. Patients with high-risk cytogenetic abnormalities should be treated in investigational protocols if they are not candidates for ICT.

U2 - 10.1016/j.clml.2014.06.015

DO - 10.1016/j.clml.2014.06.015

M3 - SCORING: Journal article

C2 - 25486954

VL - 14 Suppl

SP - S42-5

JO - CL LYMPH MYELOM LEUK

JF - CL LYMPH MYELOM LEUK

SN - 2152-2650

ER -